Early research (Phase 1)Study completedNCT03274219What this trial is testingStudy of bb21217 in Multiple MyelomaWho this might be right forMultiple Myeloma 2seventy bio 72
Testing effectiveness (Phase 2)Study completedNCT01962792What this trial is testingStudy of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Pharmacyclics LLC. 84
Early research (Phase 1)Ended earlyNCT03502577What this trial is testingBCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple MyelomaWho this might be right forRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma Fred Hutchinson Cancer Center 19
Testing effectiveness (Phase 2)Study completedNCT01592370What this trial is testingAn Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaWho this might be right forNon-Hodgkin's LymphomaHodgkin LymphomaMultiple Myeloma Bristol-Myers Squibb 320
Not applicableTemporarily pausedNCT03752541What this trial is testingEfficacy and Safety Evaluation of BCMA-UCARTWho this might be right forMultiple Myeloma Bioray Laboratories 20
Large-scale testing (Phase 3)Ended earlyNCT04649060What this trial is testingStudy of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple MyelomaWho this might be right forRelapsed Multiple MyelomaRelapsed-Refractory Multiple Myeloma Oncopeptides AB 54
Large-scale testing (Phase 3)Looking for participantsNCT07772024What this trial is testingInobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma RefractoryMultiple Myeloma in Relapse CellCentric Ltd. 450
Large-scale testing (Phase 3)Active Not RecruitingNCT06208150What this trial is testingA Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideWho this might be right forMultiple Myeloma Janssen Research & Development, LLC 838
Testing effectiveness (Phase 2)Study completedNCT02206425What this trial is testingIxazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsWho this might be right forMultiple Myeloma Oncotherapeutics 45
Testing effectiveness (Phase 2)Study completedNCT00809276What this trial is testingAllo BMT Using Matched Related/Unrelated Donors With FluBu and HiCYWho this might be right forLymphomaMultiple MyelomaLeukemia+1 more Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 92
Testing effectiveness (Phase 2)Study completedNCT01168804What this trial is testingBendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Austrian Forum Against Cancer 79
Post-approval studies (Phase 4)Study completedNCT03934684What this trial is testingStudy to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple MyelomaWho this might be right forRelapsed Refractory Multiple Myeloma Amgen 101
Early research (Phase 1)Study completedNCT01372540What this trial is testingFilanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaWho this might be right forPlasma Cell LeukemiaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma M.D. Anderson Cancer Center 76
Not applicableUnknownNCT00295997What this trial is testingDonor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic AnemiaWho this might be right forChronic Myeloproliferative DisordersKidney CancerLeukemia+4 more University of California, San Francisco 35
Testing effectiveness (Phase 2)Study completedNCT00445484What this trial is testingLenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma and Plasma Cell Neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 22
Testing effectiveness (Phase 2)Study completedNCT02119468What this trial is testingIxazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple MyelomaWho this might be right forRefractory Plasma Cell MyelomaRecurrent Plasma Cell Myeloma City of Hope Medical Center 32
Testing effectiveness (Phase 2)Ended earlyNCT03683277What this trial is testingIPD in RRMM Characterized With Genomic Abnormalities of Adverse PrognosticWho this might be right forMultiple MyelomaRelapsed and Refractory Multiple MyelomaGenetic Condition Intergroupe Francophone du Myelome 26
Large-scale testing (Phase 3)UnknownNCT00747877What this trial is testingHigh-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After ChemotherapyWho this might be right forMultiple Myeloma and Plasma Cell Neoplasm Leeds Cancer Centre at St. James's University Hospital 460
Testing effectiveness (Phase 2)Study completedNCT00051311What this trial is testingModified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System CancersWho this might be right forHematologic Neoplasms National Cancer Institute (NCI) 62
Early research (Phase 1)Study completedNCT01301807What this trial is testingPanobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple MyelomaWho this might be right forNon-Secretory Plasma Cell MyelomaPlasmacytosisRecurrent Plasma Cell Myeloma+1 more M.D. Anderson Cancer Center 63